SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share.   The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as ex ...